Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JAB-22000
- Development stage
- Preclinical
- Lead developer
- Jacobio Pharmaceuticals Co., Ltd.
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JAB-22000 is a potent, small molecule inhibitor specifically targeting the KRAS G12D mutation, developed by Jacobio Pharmaceuticals. KRAS G12D is a frequent oncogenic driver in several high-prevalence malignancies, including pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer. JAB-22000 is designed to selectively inhibit the signaling activity of the mutant KRAS protein, thereby disrupting downstream pathways essential for tumor growth and survival. Beyond its potential as a standalone therapeutic, JAB-22000 is utilized as the cytotoxic payload in Jacobio's JAB-BX600, an antibody-drug conjugate (ADC) that targets EGFR to deliver the KRAS inhibitor directly to tumor cells. As of late 2023, the program was in the preclinical stage with IND filing anticipated for the 2023-2024 period.
02
Targets
Mutant KRAS G12A peptide epitopeKRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)Kirsten rat sarcoma viral oncogene homolog G12R mutant proteinKRASG12V (KRAS G12V)Kirsten rat sarcoma viral oncogene homolog mutated proteinKRAS Q61H (Kirsten rat sarcoma viral oncogene homolog Q61H mutant)
Beyond the preview
Go deeper on JAB-22000.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JAB-22000.